Saroj Niraula

Listing my 2025 publications. Most happened to be single-author papers this year. Many topics but single theme: "Misaligned incentives drift a reasonable clinician away from patient's interest" One/two takeaways per paper in thread below.. Some behind paywall -- DM for full-text.

Register if you're around and interested.

@Dr_DTW and I will be teaching a clinical research workshop at #SFONNepal in Kathmandu on Feb 6. See you there if you are around and interested.

A Meaningful Start to the Year in Oncology Research - @sarojniraula oncodaily.com/voices/saroj-n… #Cancer #Oncology #OncoDaily #Health #Medicine @CancerWorldmag

Agree. Hard to uproot because they're embedded in design of academic incentive structure. We argued earlier this year that individual transparency is not adequate; need governance responses to realign incentives and institutional roles. Not easy! nature.com/articles/s4157…

Headlines reported 12 former FDA commissioners oppose the Trump administration's higher standards for vaccines, giving the impression that the new FDA bosses are deviating from established science. But SEC filings and OpenPayments show a swampy revolving door: Scott Gottlieb - $2.1 million from Pfizer since 2020 according to SEC filings. He was often the highest paid member of the board, where he is the lead advisor on ethics and regulatory compliance. Stephen Ostroff - $752,310 from Pfizer in consulting fees since 2020, according to OpenPayments. Mark McClellan - $3.3 million from Johnson & Johnson since 2013 according to SEC filings. He also consults Blackstone Sciences, which is led by Pfizer's former longtime top scientist whose first big investment was $750 million into Moderna's flu vaccines. Margaret Hamburg - $2.8 million from Alnylam Pharmaceuticals, which markets RNA interference (RNAi) technology Just two signatories lacked pharma ties. They are David Kessler, who executed Biden's COVID vaccine policy, and Jane Henney, who authored a prominent CDC-underwritten study defending CDC's COVID vaccine safety surveillance.

And finally in @CMAJ of @CMA_Docs Permission to Exist: Takeaway: A personal piece on earning credibility under scrutiny as an IMG in Canada. The conclusion is simple: stop auditioning for belonging. Hold your space; you don't need permission to exist! pubmed.ncbi.nlm.nih.gov/41285459/

@NatRevClinOncol Non-financial conflicts of interest: Takeaway: Most COI in medicine affecting judgment are not financial. They're insidious, invisible & affect what's believed, published, and offered to pts. Problems're structural, solutions're overdue! pubmed.ncbi.nlm.nih.gov/40903524/

Listing my 2025 publications. Most happened to be single-author papers this year. Many topics but single theme: "Misaligned incentives drift a reasonable clinician away from patient's interest" One/two takeaways per paper in thread below.. Some behind paywall -- DM for full-text.

Going Beyond Conflict of Interest Disclosure - Luca De Fiore @lucadf @sarojniraula oncodaily.com/voices/luca-de… #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd

Very important editorial!

Out today in @JCOOP_ASCO First thing first: Everyone has conflicts in some form. This is not about individuals. It is about the system!! Conflicts can lead to distorted evidence, but good news: fixing it is possible. more below... @ian_tannock ascopubs.org/doi/10.1200/OP…

@PhilosopherMD1 Thank you!

@sarojniraula What a pleasant surprise to see you on my tweet! Again, a well written and excellent paper sir.

Excellent take on surrogate endpoints. Short and to the point. ascopubs.org/doi/full/10.12…

Narrative Matters | Saroj Niraula, a Nepali-Canadian medical oncologist, reflects on the lack of progress in global cancer care delivery, and what real progress must look like. Read his story: healthaffairs.org/doi/full/10.13…

@JournalCancer @OncoAlert Thanks for sharing @JournalCancer @AmericanCancer

New #OpenAccess commentary by @sarojniraula | Rethinking prestige and dependency in global oncology 🌍 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert